Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risperidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR1D | P28221 | 2/20 | 1.00 |
| ▸ | HTR1B | P28222 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risperidone SCHEMBL16965766 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL5070793 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL27911 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL5777424 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL20578557 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL5774262 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL28382198 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL29051431 | 0.96 | DRD2 (0.92) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL3623879 | 0.96 | HTR2A (0.92) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| SCHEMBL23696626 | 0.96 | DRD2 (0.92) | DRD2HTR2AHTR1AKCNH2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029304-A1 | Method of Treating Acute Exacerbation of Schizophrenia with Long-Acting Injectable Depot Composition | LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) | 2023-01-26 | — | — | US | claimed |
| EP-4588477-B1 | PHARMACEUTICAL COMPOSITION COMPRISING NALTREXONE AND RISPERIDONE FOR USE IN PREVENTING CANNABIS RELAPSE | SHENZHEN SCIENCARE PHARMACEUTICAL CO LTD (CN) | 2026-05-27 | — | — | EP | disclosed |
| CN-122091465-A | Plasma electrospray fusion ionization source and mass spectrum combined system and detection method | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4739303-A2 | MDMA ENANTIOMER COMPOSITIONS AND METHODS FOR MODULATING AGGRESSION RESPONSE | EmpathBio, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260098847-A1 | TEXTURED FILM FOR USE IN A DISSOLUTION ADAPTER AND USES THEREOF | UNIV CONNECTICUT (US) | 2026-04-09 | — | — | US | disclosed |
| US-12594236-B2 | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition | LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) | 2026-04-07 | — | — | US | disclosed |
| US-20260069531-A1 | POLYMERIC LEUPROLIDE ACETATE FORMULATIONS | TOLMAR INTERNATIONAL LTD (IE) | 2026-03-12 | — | — | US | disclosed |
| EP-4706658-A2 | DRUG DELIVERY FORMULATIONS | MEDINCELL S.A. (FR) | 2026-03-11 | — | — | EP | disclosed |
| EP-4694864-A1 | POLYMERIC LEUPROLIDE ACETATE FORMULATIONS | Tolmar International Limited (IE) | 2026-02-18 | — | — | EP | disclosed |
| US-20250387381-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG LOADING OF LONG-ACTING IN SITU FORMING IMPLANTS AND USES THEREOF | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2025-12-25 | — | — | US | disclosed |
| US-20220288048-A1 | PIMAVANSERIN FOR TREATING SCHIZOPHRENIA OR FOR TREATING PSYCHOSIS SECONDARY TO NEURODEGENERATIVE DISORDERS OR DEPRESSIVE DISORDER | ACADIA PHARM INC (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220280646-A1 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT AND HIGH VISCOSITY LIQUID CARRIER MATERIAL | DURECT CORPORATION (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114929229-A | Method for treating antipsychotic-induced weight gain with milicolan | 科赛普特治疗学股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114685470-A | Risperidone key group derivative, immunogen, anti-risperidone specific antibody, and preparation method and application thereof | 苏州博源医疗科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20220183964-A1 | IMPLANTABLE POLYMER DEPOTS FOR THE CONTROLLED, SUSTAINED RELEASE OF THERAPEUTIC AGENTS | FOUNDRY THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| WO-2022123089-A1 | SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022091925-A1 | ROPINIROLE-CONTAINING PATCH AND METHOD FOR IMPROVING SKIN PERMEABILITY OF ROPINIROLE | 久光製薬株式会社 | 2022-05-05 | — | — | WO | disclosed |
| CN-109970760-B | ACC inhibitors and uses thereof | 吉利德阿波罗公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11285217-B2 | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material | DURECT CORPORATION (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3952847-A1 | IMPLANTABLE POLYMER DEPOTS FOR THE CONTROLLED, SUSTAINED RELEASE OF THERAPEUTIC AGENTS | Foundry Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280646-A1 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT AND HIGH VISCOSITY LIQUID CARRIER MATERIAL | HACD3, ACADM, LDHB | DRD2 1561/4885HTR2A 711/4885HTR2C 398/4885 |
| US-11285217-B2 | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material | HACD3, HACD2, ACADM | DRD2 1349/4885HTR2A 674/4885HTR2C 360/4885 |
| US-20220288048-A1 | PIMAVANSERIN FOR TREATING SCHIZOPHRENIA OR FOR TREATING PSYCHOSIS SECONDARY TO NEURODEGENERATIVE DISORDERS OR DEPRESSIVE DISORDER | SLC6A3, SNCA, NLN | DRD2 88/4885HTR2A 241/4885HTR2C 1016/4885 |
| US-20260098847-A1 | TEXTURED FILM FOR USE IN A DISSOLUTION ADAPTER AND USES THEREOF | PGRMC2, TNFSF11, PGRMC1 | DRD2 793/4885HTR2A 64/4885HTR2C 149/4885 |
| US-12594236-B2 | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition | GABRE, LPAR2, MRPS27 | DRD2 402/4885HTR2A 814/4885HTR2C 968/4885 |
| US-20260069531-A1 | POLYMERIC LEUPROLIDE ACETATE FORMULATIONS | GNRHR, LPXN, LHCGR | DRD2 931/4885HTR2A 953/4885HTR2C 1158/4885 |
| US-20250387381-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG LOADING OF LONG-ACTING IN SITU FORMING IMPLANTS AND USES THEREOF | VEGFA, ABCB11, PGR | DRD2 3225/4885HTR2A 1012/4885HTR2C 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.